UBS Group Downgrades Merck KGaA (OTCMKTS:MKKGY) to Hold

Merck KGaA (OTCMKTS:MKKGY) was downgraded by investment analysts at UBS Group from a “strong-buy” rating to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

Several other research analysts also recently commented on MKKGY. Zacks Research raised Merck KGaA from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 22nd. Jefferies Financial Group started coverage on shares of Merck KGaA in a research note on Tuesday, May 26th. They issued a “hold” rating on the stock. Finally, HSBC raised shares of Merck KGaA to a “hold” rating in a report on Monday, July 6th. Six equities research analysts have rated the stock with a Hold rating, According to MarketBeat, Merck KGaA has an average rating of “Hold”.

Merck KGaA Price Performance

Shares of MKKGY stock opened at $32.24 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.51 and a debt-to-equity ratio of 0.36. Merck KGaA has a twelve month low of $23.73 and a twelve month high of $34.19. The company has a market cap of $20.83 billion, a P/E ratio of 16.62, a P/E/G ratio of 2.62 and a beta of 0.98. The business has a fifty day simple moving average of $32.23 and a 200 day simple moving average of $29.36.

About Merck KGaA

Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.

Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.